GGrantIndex
← Leaderboards

Daniel J Merenstein

Children'S Research Institute

Google Scholar ↗PubMed ↗ORCID ↗
$17,048,763
Attributed
$27,691,766
Total exposure
7
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.3M · FY2007–25
$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$27,691,766 · 7

By mechanism

U01$21,981,541 · 2
R01$3,587,761 · 1
R33$1,193,618 · 1
R61$648,800 · 1
R34$234,279 · 1
M01$45,767 · 1

Top collaborators

Most similar at Children'S Research Institute

Same institution · by research overlap

Others in their field

Top investigators on “Participant”

Research focus

ParticipantPreventionPreventMicrobiomeUnited StatesAreaProtocols DocumentationMarylandTransmission ProcessFundingPlayBaseEnrollmentLifeAntibioticsResearch PersonnelAntiretroviral TherapyEpidemicChronicDistrict Of ColumbiaMetropolitanDiagnosisCohort StudiesMorbidity - Disease Rate

Grant awards (33)

Surviving the HIV Epidemic (S/HE) in metropolitan Washington DC - Advancing knowledge through cohort studies$2,877,028
U01 · FY2025 · HL
Surviving the HIV Epidemic (S/HE) in metropolitan Washington DC - Advancing knowledge through cohort studies$2,852,127
U01 · FY2024 · HL
Surviving the HIV Epidemic (S/HE) in metropolitan Washington DC - Advancing knowledge through cohort studies$2,839,771
U01 · FY2023 · HL
Surviving the HIV Epidemic (S/HE) in metropolitan Washington DC - Advancing knowledge through cohort studies$2,905,179
U01 · FY2022 · HL
Exploratory Pilot Studies to Demonstrate Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics$288,211
R33 · FY2022 · AT · contact PI
Surviving the HIV Epidemic (S/HE) in metropolitan Washington DC - Advancing knowledge through cohort studies$2,904,444
U01 · FY2021 · HL
A Phase II randomized controlled trial to evaluate the role of BB-12 in antibiotic-associated diarrhea and its effects on the gut microbiome$582,655
R01 · FY2021 · HD · contact PI
Exploratory Pilot Studies to Demonstrate Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics$471,997
R33 · FY2021 · AT · contact PI
A Phase II randomized controlled trial to evaluate the role of BB-12 in antibiotic-associated diarrhea and its effects on the gut microbiome$326,960
R01 · FY2021 · HD · contact PI
Surviving the HIV Epidemic (S/HE) in metropolitan Washington DC - Advancing knowledge through cohort studies$35,088
U01 · FY2021 · HL
Surviving the HIV Epidemic (S/HE) in metropolitan Washington DC - Advancing knowledge through cohort studies$2,881,859
U01 · FY2020 · HL
A Phase II randomized controlled trial to evaluate the role of BB-12 in antibiotic-associated diarrhea and its effects on the gut microbiome$619,407
R01 · FY2020 · HD · contact PI
Exploratory Pilot Studies to Demonstrate Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics$433,410
R33 · FY2020 · AT · contact PI
Surviving the HIV Epidemic (S/HE) in metropolitan Washington DC - Advancing knowledge through cohort studies$56,595
U01 · FY2020 · HL
Surviving the HIV Epidemic (S/HE) in metropolitan Washington DC - Advancing knowledge through cohort studies$54,481
U01 · FY2020 · HL
Surviving the HIV Epidemic (S/HE) in metropolitan Washington DC - Advancing knowledge through cohort studies$18,015
U01 · FY2020 · HL
Surviving the HIV Epidemic (S/HE) in metropolitan Washington DC - Advancing knowledge through cohort studies$4,251
U01 · FY2020 · HL
Surviving the HIV Epidemic (S/HE) in metropolitan Washington DC - Advancing knowledge through cohort studies$2,435,000
U01 · FY2019 · HL
A Phase II randomized controlled trial to evaluate the role of BB-12 in antibiotic-associated diarrhea and its effects on the gut microbiome$621,668
R01 · FY2019 · HD · contact PI
Surviving the HIV Epidemic (S/HE) in metropolitan Washington DC - Advancing knowledge through cohort studies$500,351
U01 · FY2019 · HL
Exploratory Pilot Studies to Demonstrate Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics$255,890
R61 · FY2019 · AT · contact PI
Surviving the HIV Epidemic (S/HE) in metropolitan Washington DC - Advancing knowledge through cohort studies$249,999
U01 · FY2019 · HL
Surviving the HIV Epidemic (S/HE) in metropolitan Washington DC - Advancing knowledge through cohort studies$23,019
U01 · FY2019 · HL
A Phase II randomized controlled trial to evaluate the role of BB-12 in antibiotic-associated diarrhea and its effects on the gut microbiome$630,449
R01 · FY2018 · HD · contact PI
Exploratory Pilot Studies to Demonstrate Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics$392,910
R61 · FY2018 · AT · contact PI
Understanding probiotic carrier format in the prevention of antibiotic-associated diarrhea - Murine Model Supplement$168,090
R01 · FY2018 · HD · contact PI
A Phase II randomized controlled trial to evaluate the role of BB-12 in antibiotic-associated diarrhea and its effects on the gut microbiome$638,532
R01 · FY2017 · HD · contact PI
Yogurt beverages as a vehicle to deliver high dose probiotics$317,035
U01 · FY2013 · AT · contact PI
Yogurt beverages as a vehicle to deliver high dose probiotics$362,308
U01 · FY2012 · AT · contact PI
Yogurt beverages as a vehicle to deliver high dose probiotics$217,704
U01 · FY2010 · AT · contact PI
Yogurt beverages as a vehicle to deliver high dose probiotics$447,287
U01 · FY2009 · AT · contact PI
The NOSES Trial, Nasal irrigation, Oral steroids, Antibiotics and Subgroup target$234,279
R34 · FY2009 · AI · contact PI
THE DRINK STUDY-DECREASING RATES OF ILLNESSES IN KIDS$45,767
M01 · FY2007 · RR · contact PI